The Cultivated B introduces n!Biomachines: fit-for-purpose bioreactors designed to easily and affordably scale cellular agriculture

The Cultivated B (TCB) has today announced the name change of its Canadian subsidiary, now embracing a broader mission. Formerly called The Cultivated B Canada and located in Burlington, Ontario, n!Biomachines (pronounced 'n factorial biomachines') is dedicated to fulfiling the commercial scalability and viability potential of industrial cellular agriculture technologies across a number of product categories. Unlike over-engineered bioreactors that were designed predominantly for pharmaceutical use, n!Biomachines delivers affordable, easy-to-operate systems for the food, dietary supplement and cosmetics industries, offering sustainable solutions that consume remarkably low amounts of electricity, in some cases as low as 150W.  

The company’s AUXO V fit-for-purpose bioreactors are engineered to focus on single applications, such as animal cells or yeast. This streamlines complex processes and eliminates the operational clutter that multifunctionality typically brings to bioprocessing. The AUXO V’s revolutionary design benefits large-scale manufacturing by improving process efficiency and drastically reducing the level of expertise needed to operate a bioreactor.  

“The mathematical term, 'n!', or n factorial, acknowledges the core of our mission: scalability and multiplication, with respect to our bioreactor capacity as well as bioprocessing opportunities for our customers,” said Dr Hamid Noori, CEO of n!Biomachines and The Cultivated B. “'Biomachines' refers to the revolutionary redesign of bioreactors to be useful across all industry sectors that want to step away from overengineered, overly complex equipment. The name n!Biomachines signifies our ambition to expand the applications of bioprocessing through affordable, sustainable and purpose-driven bioreactor design.”

Unparalleled usability, increased automation and optimized operational and equipment costs define this new generation of bioreactors for benchtop-, pilot- and industrial-scale bioprocessing without compromising production quality, safety or efficiency. With an emphasis on rapid delivery and cost-effective design, n!Biomachines unlocks bioprocessing for new industries while accelerating growth and innovation for established sectors.

“It became clear to us that the cellular agriculture industry is at an inflection point where benchtop processes are quite well-proven, but scalability and commercial viability have yet to be sufficiently addressed,” continued Dr Noori. “Our new bioreactor designs enable efficient processes and the faster delivery times needed to accelerate and integrate cellular agriculture as an additional pillar of our food production system. n!Biomachines is the answer to removing the bioreactor bottlenecks that currently prevent this emerging industry from scaling.”